Switch theme
Sign up to access all valuation multiples
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
1933
2.1K+
LTM Revenue $612M
LTM EBITDA $119M
$773M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vetoquinol has a last 12-month revenue (LTM) of $612M and a last 12-month EBITDA of $119M.
In the most recent fiscal year, Vetoquinol achieved revenue of $606M and an EBITDA of $128M.
Vetoquinol expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vetoquinol valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $612M | XXX | $606M | XXX | XXX | XXX |
| Gross Profit | $612M | XXX | $435M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $119M | XXX | $128M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $91.4M | XXX | $85.7M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $71.2M | XXX | $65.9M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vetoquinol's stock price is EUR 74 (or $83).
Vetoquinol has current market cap of EUR 873M (or $981M), and EV of EUR 688M (or $773M).
See Vetoquinol trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $773M | $981M | XXX | XXX | XXX | XXX | $5.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vetoquinol has market cap of $981M and EV of $773M.
Vetoquinol's trades at 1.3x EV/Revenue multiple, and 6.0x EV/EBITDA.
Equity research analysts estimate Vetoquinol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vetoquinol has a P/E ratio of 13.8x.
See valuation multiples for Vetoquinol and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $981M | XXX | $981M | XXX | XXX | XXX |
| EV (current) | $773M | XXX | $773M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.5x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBIT | 8.5x | XXX | 9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.8x | XXX | 14.9x | XXX | XXX | XXX |
| EV/FCF | 10.2x | XXX | 10.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVetoquinol's last 12 month revenue growth is 3%
Vetoquinol's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Vetoquinol's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vetoquinol's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vetoquinol and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
| i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
| Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
| Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vetoquinol acquired XXX companies to date.
Last acquisition by Vetoquinol was XXXXXXXX, XXXXX XXXXX XXXXXX . Vetoquinol acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vetoquinol founded? | Vetoquinol was founded in 1933. |
| Where is Vetoquinol headquartered? | Vetoquinol is headquartered in France. |
| How many employees does Vetoquinol have? | As of today, Vetoquinol has 2.1K+ employees. |
| Who is the CEO of Vetoquinol? | Vetoquinol's CEO is Mr. Matthieu Frechin. |
| Is Vetoquinol publicy listed? | Yes, Vetoquinol is a public company listed on PAR. |
| What is the stock symbol of Vetoquinol? | Vetoquinol trades under VETO ticker. |
| When did Vetoquinol go public? | Vetoquinol went public in 2006. |
| Who are competitors of Vetoquinol? | Similar companies to Vetoquinol include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
| What is the current market cap of Vetoquinol? | Vetoquinol's current market cap is $981M |
| What is the current revenue of Vetoquinol? | Vetoquinol's last 12 months revenue is $612M. |
| What is the current revenue growth of Vetoquinol? | Vetoquinol revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Vetoquinol? | Current revenue multiple of Vetoquinol is 1.3x. |
| Is Vetoquinol profitable? | Yes, Vetoquinol is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vetoquinol? | Vetoquinol's last 12 months EBITDA is $119M. |
| What is Vetoquinol's EBITDA margin? | Vetoquinol's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Vetoquinol? | Current EBITDA multiple of Vetoquinol is 6.5x. |
| What is the current FCF of Vetoquinol? | Vetoquinol's last 12 months FCF is $75.6M. |
| What is Vetoquinol's FCF margin? | Vetoquinol's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Vetoquinol? | Current FCF multiple of Vetoquinol is 10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
